Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Minakata

Showing results (731-740 of 752) with videos related to

Pageof 76
Sort By:
British Journal of Haematology|January 20, 2023
Relapsed and refractory multiple myeloma: A systematic review and network meta-analysis of the efficacy of novel therapiesDaisuke Minakata, Shin-Ichiro Fujiwara, Daizo Yokoyama, et al.
Annals of Hematology|November 27, 2018
Comparison of blast percentage calculated based on bone marrow all nucleated cells and non-erythroid cells in myelodysplastic syndromes with erythroid hyperplasiaKiyomi Mashima, Takashi Ikeda, Shin-Ichiro Kawaguchi, et al.
International Journal of Hematology|December 12, 2018
Comparison of gabexate mesilate and nafamostat mesilate for disseminated intravascular coagulation associated with hematological malignanciesDaisuke Minakata, Shin-Ichiro Fujiwara, Takashi Ikeda, et al.
Clinical Transplantation|April 6, 2024
Effects of CD34<sup>+</sup> cell dose on engraftment and long-term outcomes after allogeneic bone marrow transplantationTakashi Oyama, Shin-Ichiro Fujiwara, Ryutaro Tominaga, et al.
Blood|May 17, 2022
Daratumumab in first-line therapy is cost-effective in transplant-eligible patients with newly diagnosed myelomaChihiro Yamamoto, Daisuke Minakata, Shunsuke Koyama, et al.
Transplantation and Cellular Therapy|October 6, 2023
Cost-Effectiveness of Anti-BCMA Chimeric Antigen Receptor T Cell Therapy in Relapsed/Refractory Multiple MyelomaChihiro Yamamoto, Daisuke Minakata, Daizo Yokoyama, et al.
European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association for Cardio-Thoracic Surgery|March 13, 2016
Optimal timing of surgery for active infective endocarditis with cerebral complications: a Japanese multicentre studyYutaka Okita, Kenji Minakata, Shinji Yasuno, et al.
Circulation Journal : Official Journal of the Japanese Circulation Society|December 6, 2016
Favorable Clinical Outcomes of Transcatheter Aortic Valve Implantation in Japanese Patients - First Report From the Post-Approval K-TAVI RegistryShinya Takimoto, Naritatsu Saito, Kenji Minakata, et al.
International Journal of Hematology|February 10, 2026
Threshold for cytomegalovirus DNA PCR for preemptive treatment after allogeneic stem cell transplantationShin-Ichiro Fujiwara, Shunto Kawamura, Shun-Ichi Kimura, et al.
Transplantation and Cellular Therapy|January 19, 2025
Risk-Adapted Letermovir Prophylaxis Based on a Scoring System Predicting a Higher Burden of Cytomegalovirus Exposure After Allogeneic Hematopoietic Cell TransplantationShunto Kawamura, Shin-Ichiro Fujiwara, Shun-Ichi Kimura, et al.
Pageof 76

Showing results (731-740 of 752) with videos related to

Sort By:
Pageof 76
British Journal of Haematology|January 20, 2023
Relapsed and refractory multiple myeloma: A systematic review and network meta-analysis of the efficacy of novel therapiesDaisuke Minakata, Shin-Ichiro Fujiwara, Daizo Yokoyama, et al.
Annals of Hematology|November 27, 2018
Comparison of blast percentage calculated based on bone marrow all nucleated cells and non-erythroid cells in myelodysplastic syndromes with erythroid hyperplasiaKiyomi Mashima, Takashi Ikeda, Shin-Ichiro Kawaguchi, et al.
International Journal of Hematology|December 12, 2018
Comparison of gabexate mesilate and nafamostat mesilate for disseminated intravascular coagulation associated with hematological malignanciesDaisuke Minakata, Shin-Ichiro Fujiwara, Takashi Ikeda, et al.
Clinical Transplantation|April 6, 2024
Effects of CD34<sup>+</sup> cell dose on engraftment and long-term outcomes after allogeneic bone marrow transplantationTakashi Oyama, Shin-Ichiro Fujiwara, Ryutaro Tominaga, et al.
Blood|May 17, 2022
Daratumumab in first-line therapy is cost-effective in transplant-eligible patients with newly diagnosed myelomaChihiro Yamamoto, Daisuke Minakata, Shunsuke Koyama, et al.
Transplantation and Cellular Therapy|October 6, 2023
Cost-Effectiveness of Anti-BCMA Chimeric Antigen Receptor T Cell Therapy in Relapsed/Refractory Multiple MyelomaChihiro Yamamoto, Daisuke Minakata, Daizo Yokoyama, et al.
European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association for Cardio-Thoracic Surgery|March 13, 2016
Optimal timing of surgery for active infective endocarditis with cerebral complications: a Japanese multicentre studyYutaka Okita, Kenji Minakata, Shinji Yasuno, et al.
Circulation Journal : Official Journal of the Japanese Circulation Society|December 6, 2016
Favorable Clinical Outcomes of Transcatheter Aortic Valve Implantation in Japanese Patients - First Report From the Post-Approval K-TAVI RegistryShinya Takimoto, Naritatsu Saito, Kenji Minakata, et al.
International Journal of Hematology|February 10, 2026
Threshold for cytomegalovirus DNA PCR for preemptive treatment after allogeneic stem cell transplantationShin-Ichiro Fujiwara, Shunto Kawamura, Shun-Ichi Kimura, et al.
Transplantation and Cellular Therapy|January 19, 2025
Risk-Adapted Letermovir Prophylaxis Based on a Scoring System Predicting a Higher Burden of Cytomegalovirus Exposure After Allogeneic Hematopoietic Cell TransplantationShunto Kawamura, Shin-Ichiro Fujiwara, Shun-Ichi Kimura, et al.
Pageof 76